Access cutting-edge chronic lymphocytic leukemia treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access chronic lymphocytic leukemia specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related chronic lymphocytic leukemia treatment provided free
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Ri
Sponsor: Genmab
Check if you qualify for this chronic lymphocytic leukemia clinical trial in Palo Alto, CA
If you're searching for chronic lymphocytic leukemia treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced chronic lymphocytic leukemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.